Leonard S. Schleifer

New Capabilities

As of May 2026: Serves as executive chairman; co-architect of Regeneron's science-first model

Dupixent was approved for severe eczema in 2017 as a one-disease drug. Nine years later, it's approved for nine conditions, with the latest approval (February 24, 2026) covering allergic fungal rhinosinusitis (AFRS) — which previously had no approved treatment — and reducing the need for additional surgeries and steroid courses by 92% in trials.

Updated May 29